HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025
- Written by PR Newswire
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT Excellence Awards 2025, held in Singapore last night.